We contribute to the development of innovative therapies for those in need, leveraging our immunology and infectious disease experience and network.
Our network of internationally recognized academic leaders contribute to the design, conduct and interpretation of clinical trials in the field of immunology and vaccinology. Combined with operational excellence, this scientific expertise uniquely qualifies us as an attractive partner during the clinical development process. To customers, we are the ‘right size’ full-service clinical CRO: big enough to deliver, small enough to care.
At CR2O, we have a highly motivated and experienced cross-functional team that helps you to effectively bring your project to the clinic. Our integrated project teams enable seamless transition between the domains we service.
While covering a broad range of therapeutic areas, our primary expertise lies in the immunology and infectious disease domain, across all phases (I-IV). There, we have worked together with 75+ study centres across the globe. Prof. dr. Ab Osterhaus, our CSO and a world-renowned virologist, firmly believes that the development of intervention strategies for human infectious diseases can be accelerated through the clinical programs supported by CR2O.
I found CR2O to be highly professional and affordable in terms of services requested from them. CR2O has proven that they can match the delivery of expectations in the same way larger CROs can match these. I am very satisfied with the service and high quality of work CR2O delivers on our project and their ability to meet budgetary and timeline requirements.”
Wageningen Bioveterinary Research and BunyaVax are collaborating with CR2O within the CEPI-funded LARISSA project, in which we aim to develop a human vaccine for the prevention of Rift Valley fever: a mosquito-borne disease of animals and humans. CR2O provides essential expertise on early clinical development and I much appreciate their personal involvement, enthusiasm and professional way of working.
CR2O works in a very professional way and is also well up-to-date about knowledge and developments in the microbiome and probiotic field. CR2O is always open to input and suggestions from our side related to the research, by for example performing additional analyses or broaden the collaboration with other relevant parties. I am very content with the short lines in contact and the clear communication both related to the progress as well as in explaining the results.”